nonprofit logo

Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel

Learn about this cause: What are the reviews? Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 463673346 ✦ New york, NY ✦ Designated as a 501(c)(3)

Shop smarter and support your favorite cause at the same time! With the Give Freely browser extension, you'll automatically save money with coupons, and partner stores will donate to your chosen charity - at no extra cost to you. Start giving back with a single click. It's safe, free, and spam-free, guaranteed!

Overview

What is Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?

The Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel is a non-profit corporation, founded and managed by leading academic, medical, and research institutions - Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College. Dedicated to improving health and advancing the diagnosis, prevention, and treatment of diseases, the Institute focuses on translational research, generating proof-of-concept studies, and enhancing the scientific activities of the controlling institutions' faculty, fellows, and students within the realms of translational research, chemistry, pharmacology, and drug discovery. The Institute, with a workforce of around 40 employees, is based in New York City and is committed to developing therapeutics that arise from discoveries made in basic science labs, with a current emphasis on Alzheimer's disease, sickle cell, osteoporosis, lysosomal, lipid deposits, Parkinson's, and basal cell carcinoma.


Official website here: www.tritdi.org

What are the reviews and ratings of this charity?

Charity Navigator Rating: 81%

Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornell has received a Three-Star out of Four Star rating from Charity Navigator, reflecting its solid performance in accountability and finance. The score of 81% indicates that the organization meets a good standard of transparency and financial health, demonstrating responsible financial practices.

The organization excels in several areas, including having an entirely independent board and a high program expense ratio of nearly 94%. These factors contribute positively to its accountability, showcasing its commitment to utilizing the majority of its resources towards its mission. Furthermore, the organization adheres to best practices by having comprehensive policies related to conflicts of interest, whistleblower protections, and document retention.

However, the overall score is based solely on the Accountability & Finance beacon, suggesting there may be limited information available on other aspects like program effectiveness or community impact. While the financial health appears robust, prospective donors and supporters may want to seek additional insights into the organization's operational success and mission outcomes.


This AI summary has been generated from information found on Charity Navigator.

Is Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel legitimate?

Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel is a legitimate nonprofit organization registered as a 501(c)(3) entity. Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.


Heare are some key statistics you may want to consider:

Executive Compensation: $568,459
Professional Fundraising Fees: $0
Other Salaries and Wages: $0

For more financial information, click here


Official website here: www.tritdi.org

What is the mission statement of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?

The Sanders Tri-Institutional Therapeutics Discovery Institute is a non-profit organization controlled by leading academic, medical, and research institutions: Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College. Its mission is to enhance health and advance the diagnosis, prevention, and treatment of diseases by fostering and improving translational research, generating innovative proof-of-concept studies, and progressing the scientific activities of the controlling institutions' faculty, fellows, and students in aspects of translational research, chemistry, pharmacology, and drug discovery.


Official website here: www.tritdi.org

Who is the CEO of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?

Peter T Meinkephd is the Principal Officer of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel.


Official website here: www.tritdi.org

What is the revenue of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?

Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel's revenue in 2022 was $17,034,275.


Official website here: www.tritdi.org

Who are the executives of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel and what are their salaries?

The average compensation at Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel during 2022 was $13,865. There are 41 employees at Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel.


Here are 17 key members and their salaries:


Augustine Mk Choi Md (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $2,420,981
  • Other: $48,454
Barry Coller Md (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $685,527
  • Other: $104,781
Richard P Lifton Mdphd (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $1,221,729
  • Other: $107,573
Carl Nathan Md (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $579,683
  • Other: $63,384
David Scheinberg Md Phd (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $691,986
  • Other: $64,716
Craig B Thompson Md (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $7,914,850
  • Other: $206,110
Barbara Hempstead Md (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $742,926
  • Other: $48,354
Nathaniel Heintz Phd (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $85,040
  • Other: $20,646
Derek Tan Phd (Member Of The Board Of Dir)
  • Compensation: $0
  • Related: $500,965
  • Other: $73,859
Peter T Meinke Phd (Director)
  • Compensation: $579,341
  • Related: $0
  • Other: $65,909
Michael P Vitale (Treasurer - Effective 9/1/22)
  • Compensation: $0
  • Related: $476,990
  • Other: $124,765
James H Lapple (Treasurer - 1/1/22-6/30/22)
  • Compensation: $0
  • Related: $302,199
  • Other: $60,286
Manuel Baca (Vice President,Biologics T)
  • Compensation: $318,158
  • Related: $0
  • Other: $41,029
Paul Balderes (Sr. Director)
  • Compensation: $258,924
  • Related: $0
  • Other: $57,728
Nigel Liverton Phd (Vice President,Chemistry)
  • Compensation: $268,013
  • Related: $0
  • Other: $67,764
Patricia Aha (Vice President, Oprations)
  • Compensation: $210,802
  • Related: $0
  • Other: $40,153
Sandra Lorber (Vice President,Finance)
  • Compensation: $217,688
  • Related: $0
  • Other: $50,138


Official website here: www.tritdi.org

Where can I find the form 990 for Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel?

Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel's most recent form 990 was submitted in 2022 and can be accessed here.


Official website here: www.tritdi.org

Learn more at the official website: www.tritdi.org

Mission Statement of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel

Sanders Tri-Institutional Therapeutics Discovery Institute Inc, a non-profit corporation established by Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College, is dedicated to enhancing health and the diagnosis, prevention, and treatment of diseases. Controlled by these prominent academic, medical, and research institutions, the Institute aims to foster and improve translational research, generate innovative proof-of-concept studies, and advance the scientific activities of the controlling institutions' faculty, fellows, and students in areas of translational research, chemistry, pharmacology, and drug discovery. By nurturing collaborations across the three institutions, the Institute plays a pivotal role in bringing together expertise from various fields to tackle complex health challenges and accelerate the translation of scientific discoveries into clinical applications.

Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!

Impact




October, 2024

The Sanders Tri-Institutional Therapeutics Discovery Institute plays a crucial role in advancing public health through innovation in drug discovery and translational research. By collaborating with prestigious institutions like Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medical College, the institute effectively bridges the gap between fundamental scientific discoveries and therapeutic applications.

The focus on early-stage drug discovery is pivotal, as it enables the identification and development of promising drug candidates that have the potential to significantly alter the disease course. This includes targeted research projects addressing critical health issues such as Alzheimer's disease, sickle cell disease, osteoporosis, lysosomal storage disorders, Parkinson's disease, and basal cell carcinoma.

By providing access to specialized expertise in medicinal chemistry and compound screening, the institute fosters an environment for groundbreaking proof-of-concept studies. These studies are essential for validating the effectiveness of new treatments before they advance to clinical trials, thereby accelerating the translation of scientific breakthroughs into practical therapies.

Overall, the institute's impact is defined by its commitment to improving health outcomes, enhancing diagnostic and therapeutic strategies, and fostering the scientific growth of researchers and students involved in vital medical research.




This information is meant to be a general summary of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel. Please take the time to review official sources before making any decisions based upon the content provided here.


Financials

This financial information is from Propublica.

Revenue
$17,034,275 (2022)
Expenses
$17,034,275 (2022)
Efficiency

Other financial information:

This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: $34,984
  • Program Service Revenue: $16,999,291
  • Gross Receipts: $17,034,275

Assets and Liabilities:

  • Total Assets: $8,782,111
  • Total Liabilities: $8,782,111
  • Net Assets: $0

Want to help this charity, for free? You can click here to learn more about Give Freely

Programs

Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.

REVENUE FROM COLLABORATION AGREEM

Revenue

$11,911,800

REVENUE FROM AFFILIATION AGREEMEN

Revenue

$5,087,491

Organization Details

Founding Year

2013

Principal Officer

Peter T Meinkephd

Main Address

1300 YORK AVENUE, NEW YORK, NY, 10065

NTEE Category

Code: H99 - Medical research

If you are a representative of Sanders Tri-Institutional Therapeutics Discovery Institute Inc Co Weill Cornel and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.